StemCells (NASDAQ: STEM) has completed transplanting the six patients comprising the first cohort of its Phase II Pathway Study. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE